1-(1-氧代-2-丙烯基)-L-脯氨酸 | 60460-30-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(1-氧代-2-丙烯基)-L-脯氨酸
• 英文名称: (2''S)-1-acryloyl-pyrrolidine-2-carboxylic acid
• 英文别名: (21S)-1-acryloyl-pyrrolidine-2-carboxylic acid；(21S)-1-acryloyl-pyrrolidin-2-carboxylic acid；(2e)-1-acryloyl-pyrrolidine-2-carboxylic acid；1-acryloyl-pyrrolidine-2-carboxylic acid；1-acryloyl-pyrrolidin-2-carboxylic acid；acryloyl-pyrrolidine-2-carboxylic acid；1-Prop-2-enoylpyrrolidine-2-carboxylic acid
• CAS: 60460-30-2
• 化学式: C₈H₁₁NO₃
• 分子量: 169.18
• InChiKey: UTDSSTFBUGDVAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

文献信息

• THERMO-RESPONSIVE HYDROGEL COMPOSITIONS
  申请人：KANG-MIELER Jennifer J.

  公开号：US20120231072A1

  公开（公告）日：2012-09-13

  A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having an amino acid side chain. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nanoparticle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.

  一种热响应性水凝胶，包括具有氨基酸侧链的生物相容性单体和/或聚合物。该水凝胶在生理温度下具有热响应性，可以包含、结合或封装治疗剂，如药物组合物、生物分子和/或纳米颗粒。该水凝胶在传递治疗剂方面很有用。该水凝胶处于第一物理化学状态以用于哺乳动物。该水凝胶在哺乳动物的生理温度下具有热响应性，并转变为比第一物理化学状态更固体的第二物理化学状态。在第二物理化学状态下，热响应性水凝胶释放治疗剂。
• Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof
  申请人：Ham Young Jin

  公开号：US20080009509A1

  公开（公告）日：2008-01-10

  The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.

  本发明涉及一种新型的喹唑啉衍生物及其药学上可接受的盐，用于抑制癌细胞的生长，其制备方法以及包含其作为活性成分的制药组合物。
• Silver halide photographic light-sensitive material and process for preparing a dispersion of discrete particles of water-insoluble polymers in aqueous compositions
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0370405A1

  公开（公告）日：1990-05-30

  Matting agent dispersions can be obtained having particle size distribution (PSD) not exceeding 10 µm by (1) dissolving in a low-boiling water insoluble organic solvent a polymer, derived from the polymerization through ethylenically unsaturated groups, comprising from 0.05 to 50% by weight of units derived from an ethylenic­ally unsaturated monomer having at least one carboxyl group thereon and from 99.95 to 50% by weight of units derived from ethylenically unsaturated monomers capable of forming hydrophobic homopolymers, (2) adding to the first resulting solution a second solution of an alkali metal compound in water to transform some or all of the carboxyl groups into alkali metal carboxylate groups, and (3) dispersing the second resulting solution in aqueous compositions. Such matting agent dispersions can be introduced into the coating compositions of the outer light-insensi­tive layer of a light-sensitive silver halide photograph­ic material without causing either physical or sensito­metric harmful effects.

  通过以下方法可获得粒度分布（PSD）不超过 10 微米的消光剂分散体：(1) 在低沸点水不溶有机溶剂中溶解通过乙烯不饱和基团聚合而成的聚合物，该聚合物包括 0.05 至 50%（按重量计）由乙烯不饱和单体衍生的单元，该单体上至少有一个羧基，以及 99.95 至 50%（按重量计）由能形成疏水均聚物的乙烯不饱和单体衍生的单元，(2) 向第一种所得溶液中加入碱金属化合物在水中的第二种溶液。95%至 50%（按重量计）的单元衍生自能够形成疏水性均聚物的乙烯基不饱和单体，(2) 向第一种所得溶液中加入碱金属化合物在水中的第二种溶液，以将部分或全部羧基转化为碱金属羧基，(3) 将第二种所得溶液分散在水性组合物中。 这种消光剂分散体可以引入到感光卤化银感光材料的外感光层的涂层组合物中，而不会造成物理或感光有害影响。
• Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors
  申请人：Aurigene Discovery Technologies Limited

  公开号：US11186576B2

  公开（公告）日：2021-11-30

  The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1, R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

  本发明提供了取代的式(I)吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物，它们具有治疗作用，特别是作为选择性转录 CDK 抑制剂，包括 CDK7、CDK9、CDK12、CDK13 和 CDK18，尤其是转录 CDK7 抑制剂 其中X、环A、环B、L1、L2、R1、R2、R3、R4、R6、m、n和p具有说明书中给出的含义，以及其药学上可接受的盐，可用于治疗和预防哺乳动物中与选择性转录CDK相关的疾病或紊乱。本发明还提供了包含至少一种式（I）的取代吡唑并[1,5-a][1,3,5]三嗪和吡唑并[1,5-a]嘧啶衍生物或其药学上可接受的盐或其立体异构体的化合物和药物制剂的制备方法。
• Polymères chiraux pour la synthèse d'aminoacides énantiomériquement purs
  申请人：RHODIA CHIMIE

  公开号：EP0406124B1

  公开（公告）日：1999-11-24